Form 4: Spyre Therapeutics CFO Sells Shares for Tax Obligations

Spyre Therapeutics CFO Scott L. Burrows sold 18,428 shares of common stock to cover tax liabilities related to RSU settlement.

Summary

• Scott L. Burrows, Chief Financial Officer of Spyre Therapeutics, Inc. (SYRE), reported a transaction involving the company's common stock.
• On September 2, 2025, Mr. Burrows sold 18,428 shares of common stock at a weighted average price of $16.26 per share, with prices ranging from $16.26 to $16.30.
• This sale was a 'sell to cover' transaction, executed to satisfy tax withholding obligations in connection with the settlement of 33,738 restricted stock units (RSUs).
• The transaction was not a discretionary trade by Mr. Burrows.
• Following this transaction, Mr. Burrows beneficially owns 97,994 shares of common stock.
• The remaining beneficial ownership includes 67,476 restricted stock units (RSUs).
• These remaining RSUs are scheduled to vest in two equal installments on September 1, 2026, and September 1, 2027, contingent upon Mr. Burrows' continued employment with Spyre Therapeutics.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The transaction is a non-discretionary sale for tax purposes, which is a routine event and not indicative of a change in management's confidence. The CFO retains a substantial equity stake, aligning interests with shareholders.

Positives

• The sale was explicitly stated as a non-discretionary 'sell to cover' transaction for tax purposes, indicating it does not reflect a lack of confidence in the company's future performance.
• The CFO retains a significant beneficial ownership of 97,994 shares, including 67,476 unvested RSUs, aligning his interests with those of shareholders.

Negatives

• The transaction resulted in a reduction of the CFO's direct common stock holdings by 18,428 shares.

Risks

• The vesting of the remaining 67,476 RSUs is subject to the CFO's continued employment, posing a potential retention risk if Mr. Burrows were to depart before the vesting dates.

Future Outlook

The filing indicates future RSU vesting dates on September 1, 2026, and September 1, 2027, which are contingent on the CFO's continued employment with Spyre Therapeutics.

Management Comments

• "This sale was made to satisfy tax withholding obligations through a 'sell to cover' transaction and does not represent a discretionary trade made by the Reporting Person."

Industry Context

Insider 'sell to cover' transactions are a common and routine occurrence for executives in all industries, including biotechnology, who receive equity compensation. These sales are typically executed to manage tax liabilities upon the vesting or settlement of restricted stock units or options, and are generally not interpreted as a negative signal regarding the company's performance or future prospects, unlike discretionary sales.

Comparison to Industry Standards

• The 'sell to cover' transaction by Spyre Therapeutics' CFO aligns with standard industry practices for managing tax obligations arising from equity compensation. This method is widely used across public companies, including those in the biotechnology sector, and is considered a routine administrative action rather than a strategic investment decision. No specific comparable companies or projects are mentioned in the filing, but the practice itself is a global benchmark for executive compensation management.

Stakeholder Impact

• Shareholders: Minimal direct impact as the sale is non-discretionary for tax purposes. The CFO's continued significant holdings maintain alignment of interests.
• Employees: No direct impact on the broader employee base is indicated by this filing.

Next Steps

• Continued employment of the CFO for the vesting of remaining RSUs on September 1, 2026, and September 1, 2027.

Key Dates

Recommendation

This Form 4 reports a routine 'sell to cover' transaction by the CFO to satisfy tax obligations from RSU vesting. It is not a discretionary sale and therefore does not signal a change in management's outlook or confidence in the company. The CFO retains a substantial equity stake, aligning his interests with shareholders. As such, this filing alone does not warrant a change in investment thesis, and a 'hold' recommendation is appropriate for existing investors.

Keywords

Spyre Therapeutics, SYRE, Form 4, Insider Transaction, CFO, Stock Sale, Restricted Stock Units, RSU, Tax Liability, Sell to Cover